High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis — Stella

Recruiting

Back to Tuberculous Pericarditis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

South Africa

Nelson Mandela Academic Hospital, Mthatha, Eastern Cape

Groote Schuur Hospital, Cape Town, Western Cape

Key details

Phase

Safety & dosing

Sponsor

University of Cape Town

Enrollment target

~60 participants

Started

January 2022

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov